The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
申请公布号
SG11201502021S(A)
申请公布日期
2015.05.28
申请号
SG11201502021S
申请日期
2013.09.17
申请人
ZEALAND PHARMA A/S;BOEHRINGER INGELHEIM INTERNATIONAL GMBH
发明人
TOLBORG, JAKOB LIND;FOSGERAU, KELD;NØRREGARD, PIA;JUST, RASMUS;RIBER, DITTE;HAMPRECHT, DIETER WOLFGANG;AUGUSTIN, ROBERT;THOMAS, LEO;RIST, WOLFGANG
